bluebird bio (NASDAQ:BLUE) : Wednesdays money flow indicated an uptick to downtick ratio was at 1.14. The total value of inflow transactions on upticks was $1.69 million, whereas, the total value of outflow trades on downticks was $1.49 million. The total money flow was $0.2 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.01 million. The total value of the trades done on upticks was $0.01 million. bluebird bio (NASDAQ:BLUE) was trading with a -0.54% change over previous days close. It fell $0.22 during the day and reached $39.5. The stock was -3.12% compared to the previous weeks close.
In an insider trading activity, The Securities and Exchange Commission has divulged that Davidson David, officer (Chief Medical Officer) of Bluebird Bio, Inc., had unloaded 1,000 shares at an average price of $40.11 in a transaction dated on June 15, 2016. The total value of the transaction was worth $40,110. Currently the company Insiders own 3.5% of bluebird bio shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.88% . During last six month period, the net percent change held by insiders has seen a change of -8.88%.
The company shares have dropped -75.64% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $171.24 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $41.77 and the 200 Day Moving Average price is recorded at $47.26. bluebird bio (NASDAQ:BLUE): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $40.45 and $38.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $42.28. The buying momentum continued till the end and the stock did not give up its gains. It closed at $42.23, notching a gain of 6.33% for the day. The total traded volume was 1,164,269 . The stock had closed at $39.72 on the previous day.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.